Filtered By:
Drug: Tamoxifen
Procedure: Mammography
This page shows you your search results in order of date.
Order by Relevance | Date
Total 32 results found since Jan 2013.
False-Positive Nodes With Axillary Silicone Lymphadenopathy in an Oncologic Patient With a Rare Breast Cancer and Implant Rupture
This report is relevant as it shows that axillary lymphadenopathy caused by silicone must be considered in the evaluation of a patient with a cancer diagnosis and history of augmentation mammoplasty, especially breast cancer as the node siliconomas present a high risk of being considered a false positive metastasis.PMID:36787754 | DOI:10.1177/00031348231156777
Source: The American Surgeon - February 14, 2023 Category: Surgery Authors: Ra úl Herrera-Gutiérrez Everardo Vald és-Flores Mauricio M Garc ía-Pérez Yanko Castro-Govea Source Type: research
Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer
CONCLUSION: The addition of risk-reducing medication to screening could further decrease the risk of breast cancer death. Clinical guidelines for high-risk women should consider integrating shared decision making for risk-reducing medication and screening on the basis of individual risk factors.PMID:36455167 | DOI:10.1200/JCO.22.01342
Source: Clinical Breast Cancer - December 1, 2022 Category: Cancer & Oncology Authors: Jinani Jayasekera Amy Zhao Clyde Schechter Kathryn Lowry Jennifer M Yeh Marc D Schwartz Suzanne O'Neill Karen J Wernli Natasha Stout Jeanne Mandelblatt Allison W Kurian Claudine Isaacs Source Type: research
Preoperational diagnosis and management of breast ductal carcinoma < em > in situ < /em > arising within fibroadenoma: Two case reports
CONCLUSION: Breast DCIS arising within a fibroadenoma is rare, but patients treated with radiotherapy and endocrine therapy can have good prognosis.PMID:35611194 | PMC:PMC9048540 | DOI:10.12998/wjcc.v10.i11.3496
Source: Clinical Genitourinary Cancer - May 25, 2022 Category: Cancer & Oncology Authors: Jun Wu Ke-Wang Sun Qiu-Ping Mo Ze-Ran Yang Yuan Chen Miao-Chun Zhong Source Type: research
Time to Mammographic Density Decrease After Exposure to Tamoxifen
Oncologist. 2022 May 23:oyac104. doi: 10.1093/oncolo/oyac104. Online ahead of print.ABSTRACTMammographic density change has proven to be a reliable proxy for tamoxifen therapy response. The primary aim of this study was to identify time to tamoxifen-induced mammographic density change. We also analyzed side effects and adherence to therapy. In all, 42 women were randomized to 10 or 20 mg of daily oral tamoxifen. Mammograms were taken at baseline, 3, 6, and 9 months. Mammographic density change was measured using the automated STRATUS tool. Adverse events were monitored through a web-based questionnaire based on the FACT-ES...
Source: The Oncologist - May 23, 2022 Category: Cancer & Oncology Authors: Magnus B äcklund Mikael Eriksson Mattias Hammarstr öm Linda Thoren Jenny Bergqvist Sara Margolin Roxanna Hellgren Yvonne Wengstr öm Marike Gabrielson Kamila Czene Per Hall Source Type: research
Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial
Oncologist. 2022 May 23:oyac102. doi: 10.1093/oncolo/oyac102. Online ahead of print.ABSTRACTAlthough breast cancer incidence is increasing, there are few primary preventive initiatives. Tamoxifen can reduce breast cancer incidence but is rarely used for primary prevention due to adverse events and tolerance issues. We tested if endoxifen, a tamoxifen metabolite, applied directly to the skin of the breast, could reduce mammographic density, a proxy for therapy response. Ninety women were randomized to placebo, 10 and 20 mg of topical Z-endoxifen for 6 months. Mammographic density and symptoms were measured at baseline and s...
Source: The Oncologist - May 23, 2022 Category: Cancer & Oncology Authors: Magnus B äcklund Mikael Eriksson Marike Gabrielson Mattias Hammarstr öm Steve Quay Jenny Bergqvist Roxanna Hellgren Kamila Czene Per Hall Source Type: research
Time to Mammographic Density Decrease After Exposure to Tamoxifen
Oncologist. 2022 May 23:oyac104. doi: 10.1093/oncolo/oyac104. Online ahead of print.ABSTRACTMammographic density change has proven to be a reliable proxy for tamoxifen therapy response. The primary aim of this study was to identify time to tamoxifen-induced mammographic density change. We also analyzed side effects and adherence to therapy. In all, 42 women were randomized to 10 or 20 mg of daily oral tamoxifen. Mammograms were taken at baseline, 3, 6, and 9 months. Mammographic density change was measured using the automated STRATUS tool. Adverse events were monitored through a web-based questionnaire based on the FACT-ES...
Source: The Oncologist - May 23, 2022 Category: Cancer & Oncology Authors: Magnus B äcklund Mikael Eriksson Mattias Hammarstr öm Linda Thoren Jenny Bergqvist Sara Margolin Roxanna Hellgren Yvonne Wengstr öm Marike Gabrielson Kamila Czene Per Hall Source Type: research
Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial
Oncologist. 2022 May 23:oyac102. doi: 10.1093/oncolo/oyac102. Online ahead of print.ABSTRACTAlthough breast cancer incidence is increasing, there are few primary preventive initiatives. Tamoxifen can reduce breast cancer incidence but is rarely used for primary prevention due to adverse events and tolerance issues. We tested if endoxifen, a tamoxifen metabolite, applied directly to the skin of the breast, could reduce mammographic density, a proxy for therapy response. Ninety women were randomized to placebo, 10 and 20 mg of topical Z-endoxifen for 6 months. Mammographic density and symptoms were measured at baseline and s...
Source: The Oncologist - May 23, 2022 Category: Cancer & Oncology Authors: Magnus B äcklund Mikael Eriksson Marike Gabrielson Mattias Hammarstr öm Steve Quay Jenny Bergqvist Roxanna Hellgren Kamila Czene Per Hall Source Type: research
Time to Mammographic Density Decrease After Exposure to Tamoxifen
Oncologist. 2022 May 23:oyac104. doi: 10.1093/oncolo/oyac104. Online ahead of print.ABSTRACTMammographic density change has proven to be a reliable proxy for tamoxifen therapy response. The primary aim of this study was to identify time to tamoxifen-induced mammographic density change. We also analyzed side effects and adherence to therapy. In all, 42 women were randomized to 10 or 20 mg of daily oral tamoxifen. Mammograms were taken at baseline, 3, 6, and 9 months. Mammographic density change was measured using the automated STRATUS tool. Adverse events were monitored through a web-based questionnaire based on the FACT-ES...
Source: The Oncologist - May 23, 2022 Category: Cancer & Oncology Authors: Magnus B äcklund Mikael Eriksson Mattias Hammarstr öm Linda Thoren Jenny Bergqvist Sara Margolin Roxanna Hellgren Yvonne Wengstr öm Marike Gabrielson Kamila Czene Per Hall Source Type: research
Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial
Oncologist. 2022 May 23:oyac102. doi: 10.1093/oncolo/oyac102. Online ahead of print.ABSTRACTAlthough breast cancer incidence is increasing, there are few primary preventive initiatives. Tamoxifen can reduce breast cancer incidence but is rarely used for primary prevention due to adverse events and tolerance issues. We tested if endoxifen, a tamoxifen metabolite, applied directly to the skin of the breast, could reduce mammographic density, a proxy for therapy response. Ninety women were randomized to placebo, 10 and 20 mg of topical Z-endoxifen for 6 months. Mammographic density and symptoms were measured at baseline and s...
Source: The Oncologist - May 23, 2022 Category: Cancer & Oncology Authors: Magnus B äcklund Mikael Eriksson Marike Gabrielson Mattias Hammarstr öm Steve Quay Jenny Bergqvist Roxanna Hellgren Kamila Czene Per Hall Source Type: research
